Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer

Nicoletta Colombo • 24 Oct 2021
ESGO 2021
Cervical Cancer Gynecological Cancer Antibodies Bevacizumab Pembrolizumab
KEYNOTE-826

Nicoletta Colombo, MD, PhD, European Institute of Oncology, Milan, Italy & University of Milan-Bicocca, Milan, Italy, presents an update from KEYNOTE-826 (NCT03635567), a double-blind Phase III trial evaluating pembrolizumab versus placebo in patients with persistent, recurrent, or metastatic cervical cancer. As recently published, pembrolizumab in this patient population resulted in a significantly longer progression-free and overall survival. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Nicoletta Colombo

Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
1:19
Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
Nicoletta Colombo • 12 Sep 2022
7-year OS from SOLO-1: sustained benefit with maintenance olaparib
1:57
7-year OS from SOLO-1: sustained benefit with maintenance olaparib
Nicoletta Colombo • 12 Sep 2022
Final OS results from PAOLA-1 evaluating 1L maintenance olaparib plus bevacizumab
1:13
Final OS results from PAOLA-1 evaluating 1L maintenance olaparib plus bevacizumab
Nicoletta Colombo • 12 Sep 2022
Eductional highlights from ESGO 2021
2:28
Eductional highlights from ESGO 2021
Nicoletta Colombo • 23 Oct 2021

Related Videos

The future of antibody-drug conjugates in endometrial cancer
1:10
The future of antibody-drug conjugates in endometrial cancer
Linda Mileshkin • 30 May 2026
B7-H4-directed ADC in endometrial versus ovarian cancer
0:43
B7-H4-directed ADC in endometrial versus ovarian cancer
Linda Mileshkin • 30 May 2026
Barriers to cervical cancer screening among rural women in India
0:54
Barriers to cervical cancer screening among rural women in India
Shailendra Dandge • 31 May 2026
A community-based model for cervical cancer screening uptake in rural India
8:39
A community-based model for cervical cancer screening uptake in rural India
Shailendra Dandge • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals